SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for BIOMERICA INC (BMRA) (CIK 0000073290) (BMRA) — Jul 28, 2020

BIOMERICA INC (BMRA) (CIK 0000073290)
Date: July 28, 2020 · CIK: 0000073290 · Accession: 0000000000-20-006887

AI Filing Summary & Sentiment

File numbers found in text: 333-239980

Date
July 28, 2020
Author
Not clearly detected
Form
UPLOAD
Company
BIOMERICA INC (BMRA) (CIK 0000073290)

Letter

United States securities and exchange commission logo July 28, 2020 Zackary Irani Chairman & Chief Executive Officer Biomerica, Inc. 17571 Von Karman Avenue Irvine, California 92614 Re:Biomerica, Inc. Registration Statement on Form S-3 Filed July 21, 2020 File No. 333-239980 Dear Mr. Irani: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jason Lee, Esq.

Show Raw Text
United States securities and exchange commission logo
July 28, 2020
Zackary Irani
Chairman & Chief Executive Officer
Biomerica, Inc.
17571 Von Karman Avenue
Irvine, California 92614
Re:Biomerica, Inc.
Registration Statement on Form S-3
Filed July 21, 2020
File No. 333-239980
Dear Mr. Irani:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jason Lee, Esq.